North America Automated Cell Counters Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type and End User

The automated cell counters market in North America is expected to grow from US$ 2,908.97 million in 2022 to US$ 4,146.38 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

The biotechnology & biopharmaceutical industry is focusing on the discovery and development of drugs to treat various diseases. Cell and molecular biology have become crucial parts of the modern drug discovery process. Monitoring the interaction of cells and internal cellular activity provides critical information on cell health, changes in disease states, and the response of targets to potential therapeutic compounds. The ability to visualize biological activities at a cellular level has been a major element in drug discovery. Further, the addition of automation and high-volume screening methods allowed the testing of many compounds. Monitoring the effect of various compounds against a specific type of cancer is executed on a cellular level. For instance, automated cell counters are used to monitor the changes in cancer cell characteristics at every stage of cancer. Moreover, various webinars are held to create awareness about the techniques that are used for cell imaging and cell counting by various institutes. For instance, the ATA Scientific Instruments, in October 2020, held four new webinars that were specifically focused on cell counting and imaging for drug discovery. Thus, the increase in the discovery and development of drugs is boosting the demand for automated cell counters.

Market Overview

The North America automated cell counter market is segmented into the US, Canada, and Mexico. The market growth is attributed to the rising prevalence of chronic and infectious diseases; the growing research on cancer, biomedical, and stem cells; and a surge in government-initiated R&D activities. According to the U.S. Department of Health and Human Services, Healthy People 2030 is creating awareness on increasing preventive care for all age group. Children, adults, and elders are educated to do regular screenings, routine health check-ups, and blood tests. Thus, the government initiatives for preventive health care are expected increase the automated cell counter market in the United States.

North America Automated Cell Counters Market Segmentation

The North America automated cell counters market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into hemocytometer, flow cytometers, electrical impedance coulter counters, and spectrophotometers. The spectrophotometers segment held the largest market share in 2022. Based on end user, the market is categorized into hospitals, research laboratories, diagnostics centers, and others. The hospitals segment held the largest market share in 2022. Based on country, the market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2022.

Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Chemometec A/S; ALIGNED GENETICS; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. are the leading companies operating in the North America automated cell counters market.